

**Series-31**

**PHARMACOVIGILANCE UNIT, KMCHHSR**

**DRUG SAFETY ALERT**

**MAY – 2025**

Indian Pharmacopoeia Commission (IPC) after the preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database reveals that the following suspected drug is associated with the ADR as given below.

S.NO	SUSPECTED DRUG	INDICATIONS	ADVERSE DRUG REACTION
1	Sulfamethoxazole + Trimethoprim	For treatment of UTI, RTI's includes Bronchitis, Pneumonia, infection in Cystic fibrosis, Melioidosis, Listeriosis, Brucellosis, Granuloma Inguinale, Otitis Media, Skin infection, Pneumocystis Carnii Pneumonia	Leukopenia

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the Pharmacovigilance unit, KMCHHSR via **Email** ([pharmacovigilance@kmchihsr.edu.in](mailto:pharmacovigilance@kmchihsr.edu.in)) / **Landline No** ([04226806808](tel:04226806808)).

**Click on the below link to find the list of Monthly Drug Safety Alerts from Mar 2016 to Till date:** [https://www.ipc.gov.in/images/List\\_of\\_Drug\\_Safety\\_Alerts\\_as\\_on\\_12th\\_March\\_2025.pdf](https://www.ipc.gov.in/images/List_of_Drug_Safety_Alerts_as_on_12th_March_2025.pdf)